HIGHTIDE-B 02511Hong Kong Stock Exchange

3.4251.93%( +0.065 )
Closed: Oct 9 · Delayed · Hong Kong Stock Exchange
HIGHTIDE-B (02511) Company Profile - Company Info, Industry & Management - cibo

Company Information

Market
HKEX Main Board
Listing Date
2023-12-22
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
KYG4568L1023

Industry

Innovative Drugs & Biologics 0.02%
124 stocks in this industry
Down 52 Up 57
Industry RankingsValue (HKD)Rank
Net Profit (Last FY)-287.27M92/125
ROE (Last FY)-79.79%103/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
LIU Liping Executive Director
YU Meng Executive Director
ZHU Xun Non-Executive Director
MA Lixiong Non-Executive Director
JIANG Feng Non-Executive Director
LI Jin Independent Non-Executive Director
HUNG Tak Wai Independent Non-Executive Director
CHEN Mingyu Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-05-04.

About this page

This page shows HIGHTIDE-B (02511) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.